Efficacy and Safety of up to 2 Years of Treatment With TransCon hGH (Lonapegsomatropin) in Treatment-Naïve and Treatment-Experienced Children With Growth Hormone Deficiency

Background: Once-weekly TransCon hGH (lonapegsomatropin) is an investigational long-acting prodrug of somatropin in development for GHD. In the pivotal 52-week phase 3 heiGHt trial, lonapegsomatropin demonstrated superior annualized height velocity (AHV) compared to the same weekly dose of daily som...

Descripción completa

Detalles Bibliográficos
Autores principales: Maniatis, Aristides K, Casella, Samuel J, Nadgir, Ulhas M, Hofman, Paul, Saenger, Paul, Chertok, Elena, Aghajanova, Elena M, Song, Wenjie, Mao, Meng, Chessler, Steven D, Komirenko, Allison, Beckert, Michael, Shu, Aimee D, Thornton, Paul S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Pediatric Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090180/
http://dx.doi.org/10.1210/jendso/bvab048.1378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090180/
http://dx.doi.org/10.1210/jendso/bvab048.1378

Ejemplares similares